Danaos Corporation vs Exelixis Inc. Common Stock — how do they compare? Danaos Corporation trades at $171.44 (market cap $3.10B), while Exelixis Inc. Common Stock trades at $58.72 (market cap $14.62B). The key difference: Exelixis Inc. Common Stock is far larger — about 4.7× Danaos Corporation's market cap, and Danaos Corporation pays a 2.35% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and Exelixis Inc. Common Stock for 0 Days on average.
| DAC | EXEL | |
|---|---|---|
Market Cap | $3.10B | $14.62B |
Volume | 286,008 | 2,684,957 |
Sector | Industrials | Health |
52-Week High | $170.22 | $59.13 |
52-Week Low | $84.05 | $34.54 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $3.08B | $13.95B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.
The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →